Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Ocular adnexal mucosa-associated lymphoid tissue lymphoma: a narrative review

  • Chung, Hyun Uk (Yeungnam Eye Center, Yeungnam University Hospital) ;
  • Son, Jun Hyuk (Department of Ophthalmology, Yeungnam University College of Medicine)
  • Received : 2021.06.21
  • Accepted : 2021.08.12
  • Published : 2022.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Lymphoma is the most common primary tumor of the orbit, accounting for 55% of all orbital malignancies. When divided into histopathological subtypes, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) comprises the largest proportion. Clinical manifestations are unspecific, but in patients with slow-growing painless orbital mass, or red conjunctival lesion suggestive of 'salmon patch', ocular adnexa lymphoma (OAL) should be suspected. Although the pathogenetic mechanism of ocular adnexal MALT lymphoma (OAML) is not yet fully understood, the relationship between OAML and Chlamydia psittaci has been hypothesized recently, similar to that between gastric MALT lymphoma and Helicobacter pylori. This suggests a new treatment option for OAML; bacterial eradication therapy with systemic antibiotics. Several other treatment methods for OAML have been introduced, but no treatment guidelines have been established yet. In this article, we summarize the current knowledge on the clinical features, pathogenesis, diagnostic methods, therapeutic strategies, and prognosis of OAML.

Keywords

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017.
  2. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848-57. https://doi.org/10.1016/S0140-6736(12)60605-9
  3. Ahmed S, Shahid RK, Sison CP, Fuchs A, Mehrotra B. Orbital lymphomas: a clinicopathologic study of a rare disease. Am J Med Sci 2006;331:79-83. https://doi.org/10.1097/00000441-200602000-00013
  4. Demirci H, Shields CL, Shields JA, Honavar SG, Mercado GJ, Tovilla JC. Orbital tumors in the older adult population. Ophthalmology 2002;109:243-8. https://doi.org/10.1016/S0161-6420(01)00932-0
  5. Margo CE, Mulla ZD. Malignant tumors of the orbit: analysis of the Florida Cancer Registry. Ophthalmology 1998;105:185-90. https://doi.org/10.1016/S0161-6420(98)92107-8
  6. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma. Cancer 1983;52:1410-6. https://doi.org/10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3
  7. Rosado MF, Byrne GE Jr, Ding F, Fields KA, Ruiz P, Dubovy SR, et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood 2006;107:467-72. https://doi.org/10.1182/blood-2005-06-2332
  8. Akpek EK, Polcharoen W, Ferry JA, Foster CS. Conjunctival lymphoma masquerading as chronic conjunctivitis. Ophthalmology 1999;106:757-60. https://doi.org/10.1016/S0161-6420(99)90163-X
  9. Bhatia S, Paulino AC, Buatti JM, Mayr NA, Wen BC. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 2002;54:818-23. https://doi.org/10.1016/S0360-3016(02)02966-8
  10. Martinet S, Ozsahin M, Belkacemi Y, Landmann C, Poortmans P, Oehlere C, et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;55:892-8. https://doi.org/10.1016/S0360-3016(02)04159-7
  11. Olsen TG, Heegaard S. Orbital lymphoma. Surv Ophthalmol 2019;64:45-66. https://doi.org/10.1016/j.survophthal.2018.08.002
  12. Uno T, Isobe K, Shikama N, Nishikawa A, Oguchi M, Ueno N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer 2003;98:865-71. https://doi.org/10.1002/cncr.11539
  13. Sjo LD. Ophthalmic lymphoma: epidemiology and pathogenesis. Acta Ophthalmol 2009;87(Thesis 1):1-20. https://doi.org/10.1111/j.1755-3768.2008.01478.x
  14. van der Gaag R. Immunological responses in the eyelid and orbit. Eye (Lond) 1988;2(Pt 2):158-63. https://doi.org/10.1038/eye.1988.29
  15. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002;3:97-104. https://doi.org/10.1016/S1470-2045(02)00651-4
  16. Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell'Oro S, Fleischhauer K, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586-94. https://doi.org/10.1093/jnci/djh102
  17. Byrne GI, Ojcius DM. Chlamydia and apoptosis: life and death decisions of an intracellular pathogen. Nat Rev Microbiol 2004;2:802-8. https://doi.org/10.1038/nrmicro1007
  18. Collina F, De Chiara A, De Renzo A, De Rosa G, Botti G, Franco R. Chlamydia psittaci in ocular adnexa MALT lymphoma: a possible role in lymphomagenesis and a different geographical distribution. Infect Agent Cancer 2012;7:8. https://doi.org/10.1186/1750-9378-7-8
  19. Chanudet E, Zhou Y, Bacon CM, Wotherspoon AC, MullerHermelink HK, Adam P, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol 2006;209:344-51. https://doi.org/10.1002/path.1984
  20. Coupland SE. Molecular pathology of lymphoma. Eye (Lond) 2013;27:180-9. https://doi.org/10.1038/eye.2012.247
  21. Daibata M, Nemoto Y, Togitani K, Fukushima A, Ueno H, Ouchi K, et al. Absence of Chlamydia psittaci in ocular adnexal lymphoma from Japanese patients. Br J Haematol 2006;132: 651-2. https://doi.org/10.1111/j.1365-2141.2005.05943.x
  22. Mulder MM, Heddema ER, Pannekoek Y, Faridpooya K, Oud ME, Schilder-Tol E, et al. No evidence for an association of ocular adnexal lymphoma with Chlamydia psittaci in a cohort of patients from the Netherlands. Leuk Res 2006;30:1305-7. https://doi.org/10.1016/j.leukres.2005.12.003
  23. Vargas RL, Fallone E, Felgar RE, Friedberg JW, Arbini AA, Andersen AA, et al. Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci?: the University of Rochester experience. Leuk Res 2006;30:547-51. https://doi.org/10.1016/j.leukres.2005.09.012
  24. Bayraktar S, Bayraktar UD, Stefanovic A, Lossos IS. Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients. Br J Haematol 2011;152:72-80. https://doi.org/10.1111/j.1365-2141.2010.08429.x
  25. Bernardini FP, Bazzan M. Lymphoproliferative disease of the orbit. Curr Opin Ophthalmol 2007;18:398-401. https://doi.org/10.1097/ICU.0b013e3282be8fbb
  26. Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, et al. Chlamydophila psittaci eradication with doxycycline as firstline targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 2012;30:2988-94. https://doi.org/10.1200/JCO.2011.41.4466
  27. Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst 2006;98:1375-82. https://doi.org/10.1093/jnci/djj373
  28. Ferreri AJ, Viale E, Guidoboni M, Resti AG, De Conciliis C, Politi L, et al. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol 2006;17:769-72. https://doi.org/10.1093/annonc/mdl027
  29. Fischbach W. Gastric MALT lymphoma: update on diagnosis and treatment. Best Pract Res Clin Gastroenterol 2014;28: 1069-77. https://doi.org/10.1016/j.bpg.2014.09.006
  30. Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011;25:691-700. https://doi.org/10.1097/QAD.0b013e3283437f77
  31. Riedel DJ, Rositch AF, Redfield RR, Blattner WA. HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population. Leuk Lymphoma 2016; 57:306-12. https://doi.org/10.3109/10428194.2015.1055483
  32. Bruyand M, Thiebaut R, Lawson-Ayayi S, Joly P, Sasco AJ, Mercie P, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009;49:1109-16. https://doi.org/10.1086/605594
  33. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009;10:1152-9. https://doi.org/10.1016/S1470-2045(09)70282-7
  34. Zoufaly A, Stellbrink HJ, Heiden MA, Kollan C, Hoffmann C, van Lunzen J, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009;200:79-87. https://doi.org/10.1086/599313
  35. Teixeira Mendes LS, Wotherspoon A. Marginal zone lymphoma: associated autoimmunity and auto-immune disorders. Best Pract Res Clin Haematol 2017;30:65-76. https://doi.org/10.1016/j.beha.2016.07.006
  36. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44. https://doi.org/10.1001/archinte.165.20.2337
  37. Du MQ. MALT lymphoma: many roads lead to nuclear factor-κb activation. Histopathology 2011;58:26-38. https://doi.org/10.1111/j.1365-2559.2010.03699.x
  38. Ruiz A, Reischl U, Swerdlow SH, Hartke M, Streubel B, Procop G, et al. Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter analysis of 34 cases including interphase molecular cytogenetics and PCR forChlamydia psittaci. Am J Surg Pathol 2007;31:792-802. https://doi.org/10.1097/01.pas.0000249445.28713.88
  39. Tanimoto K, Sekiguchi N, Yokota Y, Kaneko A, Watanabe T, Maeshima AM, et al. Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. BMC Cancer 2006;6:249. https://doi.org/10.1186/1471-2407-6-249
  40. Priego G, Majos C, Climent F, Muntane A. Orbital lymphoma: imaging features and differential diagnosis. Insights Imaging 2012;3:337-44. https://doi.org/10.1007/s13244-012-0156-1
  41. Eissa L, Abdel Razek AA, Helmy E. Arterial spin labeling and diffusion-weighted MR imaging: utility in differentiating idiopathic orbital inflammatory pseudotumor from orbital lymphoma. Clin Imaging 2021;71:63-8. https://doi.org/10.1016/j.clinimag.2020.10.057
  42. Politi LS, Forghani R, Godi C, Resti AG, Ponzoni M, Bianchi S, et al. Ocular adnexal lymphoma: diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring. Radiology 2010;256:565-74. https://doi.org/10.1148/radiol.10100086
  43. Isaacson PG, Norton AJ. Extranodal lymphomas. Edinburgh: Churchill Livingstone; 1996.
  44. Mannami T, Yoshino T, Oshima K, Takase S, Kondo E, Ohara N, et al. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod Pathol 2001;14:641-9. https://doi.org/10.1038/modpathol.3880366
  45. Kremer M, Cabras AD, Fend F, Schulz S, Schwarz K, Hoefler H, et al. PCR analysis of IgH-gene rearrangements in small lymphoid infiltrates microdissected from sections of paraffin-embedded bone marrow biopsy specimens. Hum Pathol 2000;31: 847-53. https://doi.org/10.1053/hupa.2000.8445
  46. Adachi A, Tamaru J, Kaneko K, Kuroda H, Miura I, Kojima T, et al. No evidence of a correlation between BCL10 expression and API2-MALT1 gene rearrangement in ocular adnexal MALT lymphoma. Pathol Int 2004;54:16-25. https://doi.org/10.1111/j.1440-1827.2004.01580.x
  47. Coupland SE, Damato B. Lymphomas involving the eye and the ocular adnexa. Curr Opin Ophthalmol 2006;17:523-31. https://doi.org/10.1097/00055735-200612000-00008
  48. Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Stein H. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol 2004;242:130-45. https://doi.org/10.1007/s00417-003-0831-5
  49. Coupland SE, Krause L, Delecluse HJ, Anagnostopoulos I, Foss HD, Hummel M, et al. Lymphoproliferative lesions of the ocular adnexa: analysis of 112 cases. Ophthalmology 1998;105: 1430-41. https://doi.org/10.1016/S0161-6420(98)98024-1
  50. Ferreri AJ, Dolcetti R, Du MQ, Doglioni C, Resti AG, Politi LS, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol 2008;19:835-46. https://doi.org/10.1093/annonc/mdm513
  51. Franco R, Camacho FI, Caleo A, Staibano S, Bifano D, De Renzo A, et al. Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. Mod Pathol 2006;19:1055-67. https://doi.org/10.1038/modpathol.3800597
  52. Bouali S, Said IB, Yedeas MD, Abderrahmen K, Maatar N, Boubaker A, et al. Primary sporadic Burkitt lymphoma of the orbit, clinical characteristics, management, and outcomes: a case study. Childs Nerv Syst 2016;32:437-40. https://doi.org/10.1007/s00381-016-3018-1
  53. Rasmussen P, Sjo LD, Prause JU, Ralfkiaer E, Heegaard S. Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol 2009;93:1047-51. https://doi.org/10.1136/bjo.2008.146910
  54. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368-76. https://doi.org/10.3322/canjclin.55.6.368
  55. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
  56. Coupland SE, White VA, Rootman J, Damato B, Finger PT. A TNM-based clinical staging system of ocular adnexal lymphomas. Arch Pathol Lab Med 2009;133:1262-7. https://doi.org/10.5858/133.8.1262
  57. Rosenberg SA, Boiron M, DeVita VT Jr, Johnson RE, Lee BJ, Ultmann JE, Viamonte M Jr. Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Res 1971;31:1862-3.
  58. Graue GF, Finger PT, Maher E, Della Rocca D, Della Rocca R, Lelli GJ Jr, et al. Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor. Eur J Ophthalmol 2013;23:344-55. https://doi.org/10.5301/ejo.5000224
  59. Lee SE, Paik JS, Cho WK, Choi BO, Lee SN, Jung SE, et al. Feasibility of the TNM-based staging system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Am J Hematol 2011;86:262-6. https://doi.org/10.1002/ajh.21963
  60. Amin MB, Edge SB, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
  61. Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim SW, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 2006;17: 135-40. https://doi.org/10.1093/annonc/mdj025
  62. Cohen VM. Treatment options for ocular adnexal lymphoma (OAL). Clin Ophthalmol 2009;3:689-92. https://doi.org/10.2147/OPTH.S5828
  63. Fung CY, Tarbell NJ, Lucarelli MJ, Goldberg SI, Linggood RM, Harris NL, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003;57:1382-91. https://doi.org/10.1016/S0360-3016(03)00767-3
  64. Bolek TW, Moyses HM, Marcus RB Jr, Gorden L 3rd, Maiese RL, Almasri NM, et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 1999;44:31-6. https://doi.org/10.1016/S0360-3016(98)00535-5
  65. Goda JS, Le LW, Lapperriere NJ, Millar BA, Payne D, Gospodarowicz MK, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys 2011;81: e659-66. https://doi.org/10.1016/j.ijrobp.2011.03.050
  66. Stafford SL, Kozelsky TF, Garrity JA, Kurtin PJ, Leavitt JA, Martenson JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol 2001;59:139-44. https://doi.org/10.1016/S0167-8140(00)00328-5
  67. Yen MT, Bilyk JR, Wladis EJ, Bradley EA, Mawn LA. Treatments for ocular adnexal lymphoma: a report by the American Academy of Ophthalmology. Ophthalmology 2018;125:127-36. https://doi.org/10.1016/j.ophtha.2017.05.037
  68. Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys 2013;86:930-5. https://doi.org/10.1016/j.ijrobp.2013.04.035
  69. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 2017; 39:1095-100. https://doi.org/10.1002/hed.24717
  70. Ben Simon GJ, Cheung N, McKelvie P, Fox R, McNab AA. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 2006;113:1209-13. https://doi.org/10.1016/j.ophtha.2006.01.057
  71. Jager G, Neumeister P, Quehenberger F, Wohrer S, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 2006;17:1722-3. https://doi.org/10.1093/annonc/mdl126
  72. Raderer M, Wohrer S, Bartsch R, Prager G, Drach J, Hejna M, et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:8442-6. https://doi.org/10.1200/JCO.2004.00.8532
  73. Zinzani PL, Stefoni V, Musuraca G, Tani M, Alinari L, Gabriele A, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004;100:2190-4. https://doi.org/10.1002/cncr.20237
  74. Kim JS, Kang SH, Moon HS, Sung JK, Jeong HY. Clinical outcome of eradication therapy for gastric mucosa-associated lymphoid tissue lymphoma according to H. pylori infection status. Gastroenterol Res Pract 2016;2016:6794848. https://doi.org/10.1155/2016/6794848
  75. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-53. https://doi.org/10.1038/nrc1409
  76. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-6. https://doi.org/10.1016/0140-6736(91)92035-Z
  77. Yoo C, Ryu MH, Huh J, Park JH, Kang HJ, Ahn HS, et al. Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea. Am J Hematol 2007;82:821-3. https://doi.org/10.1002/ajh.20962
  78. Liu YC, Ohyashiki JH, Ito Y, Iwaya K, Serizawa H, Mukai K, et al. Chlamydia psittaci in ocular adnexal lymphoma: Japanese experience. Leuk Res 2006;30:1587-9. https://doi.org/10.1016/j.leukres.2006.01.015
  79. de Cremoux P, Subtil A, Ferreri AJ, Vincent-Salomon A, Ponzoni M, Chaoui D, et al. Re: Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2006;98:365-6.
  80. Gracia E, Froesch P, Mazzucchelli L, Martin V, RodriguezAbreu D, Jimenez J, et al. Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. Leuk Lymphoma 2007;48:104-8. https://doi.org/10.1080/10428190600908174
  81. Zhang GS, Winter JN, Variakojis D, Reich S, Lissner GS, Bryar P, et al. Lack of an association between Chlamydia psittaci and ocular adnexal lymphoma. Leuk Lymphoma 2007;48:577-83. https://doi.org/10.1080/10428190601132105
  82. Han JJ, Kim TM, Jeon YK, Kim MK, Khwarg SI, Kim CW, et al. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Ann Hematol 2015;94:575-81. https://doi.org/10.1007/s00277-014-2240-8
  83. Grunberger B, Hauff W, Lukas J, Wohrer S, Zielinski CC, Streubel B, et al. 'Blind' antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol 2006;17:484-7. https://doi.org/10.1093/annonc/mdj143
  84. Tuncer S, Tanyildiz B, Basaran M, Buyukbabani N, Dogan O. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience. Curr Eye Res 2015;40:780-5. https://doi.org/10.3109/02713683.2014.959605
  85. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000;27(6 Suppl 12):17-24.
  86. Annibali O, Chiodi F, Sarlo C, Cortes M, Quaranta-Leoni FM, Quattrocchi C, et al. Rituximab as single agent in primary MALT lymphoma of the ocular adnexa. Biomed Res Int 2015;2015:895105. https://doi.org/10.1155/2015/895105
  87. Ferreri AJ, Ponzoni M, Martinelli G, Muti G, Guidoboni M, Dolcetti R, et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 2005;90:1578-9.
  88. Rigacci L, Nassi L, Puccioni M, Mappa S, Polito E, Dal Pozzo S, et al. Rituximab and chlorambucil as first-line treatment for lowgrade ocular adnexal lymphomas. Ann Hematol 2007;86:565-8. https://doi.org/10.1007/s00277-007-0301-y
  89. Knudsen MK, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Clinicopathological features of ocular adnexal mantle-cell lymphoma in an international multicenter cohort. JAMA Ophthalmol 2017;135:1367-74. https://doi.org/10.1001/jamaophthalmol.2017.4810
  90. Rasmussen PK. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features. Acta Ophthalmol 2013;91(Thesis 5):1-27. https://doi.org/10.1111/aos.12189
  91. Blasi MA, Gherlinzoni F, Calvisi G, Sasso P, Tani M, Cellini M, et al. Local chemotherapy with interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report. Ophthalmology 2001;108:559-62. https://doi.org/10.1016/S0161-6420(00)00591-1
  92. Blasi MA, Tiberti AC, Valente P, Laguardia M, Sammarco MG, Balestrazzi A, et al. Intralesional interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results. Ophthalmology 2012;119:494-500. https://doi.org/10.1016/j.ophtha.2011.09.008
  93. Lachapelle KR, Rathee R, Kratky V, Dexter DF. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b. Arch Ophthalmol 2000;118:284-5.
  94. Jenkins C, Rose GE, Bunce C, Wright JE, Cree IA, Plowman N, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 2000;84:907-13. https://doi.org/10.1136/bjo.84.8.907
  95. McKelvie PA, McNab A, Francis IC, Fox R, O'Day J. Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Exp Ophthalmol 2001;29:387-93. https://doi.org/10.1046/j.1442-9071.2001.00450.x
  96. Sullivan TJ, Whitehead K, Williamson R, Grimes D, Schlect D, Brown I, et al. Lymphoproliferative disease of the ocular adnexa: a clinical and pathologic study with statistical analysis of 69 patients. Ophthalmic Plast Reconstr Surg 2005;21:177-88. https://doi.org/10.1097/01.IOP.0000159173.42243.AD
  97. Jenkins C, Rose GE, Bunce C, Cree I, Norton A, Plowman PN, et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye (Lond) 2003;17:809-20. https://doi.org/10.1038/sj.eye.6700379
  98. Moslehi R, Devesa SS, Schairer C, Fraumeni JF Jr. Rapidly increasing incidence of ocular non-hodgkin lymphoma. J Natl Cancer Inst 2006;98:936-9. https://doi.org/10.1093/jnci/djj248
  99. Cho EY, Han JJ, Ree HJ, Ko YH, Kang YK, Ahn HS, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol 2003;73:87-96. https://doi.org/10.1002/ajh.10332
  100. Lee JL, Kim MK, Lee KH, Hyun MS, Chung HS, Kim DS, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 2005;84:13-8. https://doi.org/10.1007/s00277-004-0914-3